Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (‘Registry’)
Zeynep Belce Erton(Hospital for Special Surgery), Doruk Erkan(Hospital for Special Surgery), Savino Sciascia(Ospedale San Giovanni Bosco), Ricard Cervera(Hospital Clínic de Barcelona), Lanlan Ji(Peking University), Yu Zuo(University of Michigan), Laura Andréoli(Institute for Rheumatic Diseases (Japan)), M. Á. Aguirre(Instituto Maimónides de Investigación Biomédica de Córdoba), D. Ware Branch(University of Utah), Maria Gerosa(Istituto Ortopedico Gaetano Pini), Maria G. Tektonidou(National and Kapodistrian University of Athens), Paul R. Fortin(Centre hospitalier de l'Université Laval), Michelle Petri(Johns Hopkins University), Danieli Andrade(Universidade de São Paulo), Tatsuya Atsumi(Hokkaido University), Amaia Ugarte(BioCruces Health research Institute), Guilherme Ramires de Jesús(Universidade do Estado do Rio de Janeiro), Ecem Sevim(Albert Einstein College of Medicine), Vittorio Pengo(University of Padua)
Cited by 41
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840